Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241562 · ClinicalTrials.gov registry record
Validation of a Novel Cortical Biomarker Signature for Pain
A clinical trial, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 159
- Enrollment target
NCT04241562: Completed study, sponsored by University of Maryland, Baltimore.
NCT04241562 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04241562 has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
Study Summary
The study aims to undertake analytical validation of an brain biomarker in healthy participants experiencing a model of sustained temporomandibular pain. The biomarker could detect participants at greater risk of developing more severe pain.
Primary Outcome
Pain sensitivity
Interventions
- OTHER Injection of Nerve Growth Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2022-10-10 |
What the finished NCT04241562 record still lists
NCT04241562 is an observational study that tracks outcomes without assigning an intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Injection of Nerve Growth Factor is the first listed.
NCT04241562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04241562 about?
NCT04241562 is a clinical study titled "Validation of a Novel Cortical Biomarker Signature for Pain". The study aims to undertake analytical validation of an brain biomarker in healthy participants experiencing a model of sustained temporomandibular pain. The biomarker could detect participants at greater risk of developing more severe pain.
What is the current status of trial NCT04241562?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2020-11-04. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT04241562?
The interventions under investigation include: Injection of Nerve Growth Factor (OTHER).
Who is sponsoring clinical trial NCT04241562?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI